Summarized by Masters of Longevity from Longevity Technology.
Examine how a new at-home subcutaneous autoinjector changes Alzheimer’s treatment delivery and reduces logistical barriers for long-term patients and caregivers.
Key Takeaways
- Subcutaneous autoinjector formulation of lecanemab received FDA approval and launched in the US.
- Initiation dose is 500 mg delivered as two 250 mg autoinjector injections.
- MRI monitoring remains required to track ARIA brain swelling or bleeding risk.
